The Wistar Institute and Stanford Medicine to begin phase 2 clinical trial of VK-2019 in patients with Epstein-Barr virus (EBV)-positive advanced nasopharyngeal carcinoma
PHILADELPHIA — (Jan. 5, 2022) — The Wistar Institute announces the initiation of a Phase 2 clinical study of VK-2019 ...